Drugs / CD34+ Hematopoietic Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07408583 | Jan 2028 → Jul 2031 expected | Fanconi anemia, anemia, congenital hypoplastic, with multiple congenital anomalies/intellectual disability syndrome, bone marrow failure syndrome, hereditary neoplastic syndrome | Agnieszka Czechowicz | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34+ Hematopoietic Stem Cells | “Single-dose IUHSCT Administration of Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus Enriched CD34+ Hematopoietic Stem Cells Administered in...” NCT07408583 ↗ |
| Modality | Cell therapy | “The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells” NCT07408583 ↗ |
| Route | Other | “Administered in Utero via fetal injection” NCT07408583 ↗ |